Weishaupt, Jochen Hans

[["dc.bibliographiccitation.firstpage","675"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Neurochemistry"],["dc.bibliographiccitation.lastpage","686"],["dc.bibliographiccitation.volume","97"],["dc.contributor.author","Meuer, Katrin"],["dc.contributor.author","Pitzer, Claudia"],["dc.contributor.author","Teismann, Peter"],["dc.contributor.author","Krüger, Carola"],["dc.contributor.author","Göricke, Bettina"],["dc.contributor.author","Laage, Rico"],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Peters, Kerstin"],["dc.contributor.author","Schlachetzki, Johannes C. M."],["dc.contributor.author","Kobayashi, Kazuto"],["dc.contributor.author","Dietz, Gunnar P. H."],["dc.contributor.author","Weber, Daniela"],["dc.contributor.author","Ferger, Boris"],["dc.contributor.author","Schäbitz, Wolf-Rüdiger"],["dc.contributor.author","Bach, Alfred"],["dc.contributor.author","Schulz, Jörg B."],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Schneider, Armin"],["dc.contributor.author","Weishaupt, Jochen H."],["dc.date.accessioned","2017-09-07T11:53:06Z"],["dc.date.available","2017-09-07T11:53:06Z"],["dc.date.issued","2006"],["dc.description.abstract","We have recently shown that the hematopoietic Granulocyte-Colony Stimulating Factor (G-CSF) is neuroprotective in rodent stroke models, and that this action appears to be mediated via a neuronal G-CSF receptor. Here, we report that the G-CSF receptor is expressed in rodent dopaminergic substantia nigra neurons, suggesting that G-CSF might be neuroprotective for dopaminergic neurons and a candidate molecule for the treatment of Parkinson's disease. Thus, we investigated protective effects of G-CSF in 1-methyl-4-phenylpyridinium (MPP+)-challenged PC12 cells and primary neuronal midbrain cultures, as well as in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease. Substantial protection was found against MPP+-induced dopaminergic cell death in vitro. Moreover, subcutaneous application of G-CSF at a dose of 40 mu g/Kg body weight daily over 13 days rescued dopaminergic substantia nigra neurons from MPTP-induced death in aged mice, as shown by quantification of tyrosine hydroxylase-positive substantia nigra cells. Using HPLC, a corresponding reduction in striatal dopamine depletion after MPTP application was observed in G-CSF-treated mice. Thus our data suggest that G-CSF is a novel therapeutic opportunity for the treatment of Parkinson's disease, because it is well-tolerated and already approved for the treatment of neutropenic conditions in humans."],["dc.identifier.doi","10.1111/j.1471-4159.2006.03727.x"],["dc.identifier.gro","3143697"],["dc.identifier.isi","000236798600007"],["dc.identifier.pmid","16573658"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1240"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0022-3042"],["dc.title","Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]